Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic...
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr...
Ozempic® improved maximum walking distance by 13% vs placebo in adults with type 2 diabetes and peripheral artery disease (PAD)...
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides...
RALEIGH, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone...
On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL...
NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- “Tren-Max is the safe and legal steroid alternative to Trenbolone Acetate" Our...
DELRAY BEACH, Fla., March 20, 2025 /PRNewswire/ -- The global US Remote Patient Monitoring Market, valued at US$14.15 billion in...
New pathways for cardiovascular health, weight management, and diabetes improve well-being while lowering healthcare costsPITTSBURGH, March 20, 2025 (GLOBE NEWSWIRE)...
Next-gen smart mirror integrates AI-powered health monitoring with seamless 4G connectivity for enhanced telehealth, retail, and wellness applications TORONTO, March...
Received FDA Clearance for the HeartBeam System – an At-Home, High-Fidelity Heart Monitoring Technology Commenced Early Access Program to Attain...
CHATHAM, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed...
LOS ANGELES, March 08, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious...
RALEIGH, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, is pleased to announce that the U.S. Food and Drug...
MyOme Launches Integrated Risk Tool for Coronary Artery Disease MENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ -- MyOme, Inc., a...
-- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events...
– Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first...
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen...
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended...
Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the...